AntibodySystem provides structure-specific antibodies for R-loops (S9.6), G-quadruplexes (BG4), Z-DNA/Z-RNA (Z22), dsRNA, dsDNA, ssDNA, and ssRNA. Support DRIP-seq, ChIP, IF, ELISA, and viral research. Reliable tools for nucleic acid structure and genome regulation studies.

AAIC 2026 highlights Donanemab long-term data, Lecanemab subcutaneous autoinjector, and Tau-targeted ASO and antibody therapies. Alzheimer’s research moves beyond Aβ toward combined Aβ+Tau multi-target strategies.

In June 2026, AntibodySystem products continued to support cutting-edge research across immunology, infectious diseases, oncology, regenerative medicine, and cardiovascular biology. Studies citing AntibodySystem reagents were published in leading journals including MedComm, iScience, and Technology in Cancer Research & Treatment and more, highlighting their applications in therapeutic antibody discovery, targeted anticoagulant development, cancer biomarker validation, and more.

Australia reports rising diphtheria cases and first border detection of H5N1 HPAI. This article reviews pathogen mechanisms, transmission risks, and surveillance importance, with research reagents for infectious disease studies.

This series of products are mouse monoclonal antibodies specifically targeting the IgM heavy chain constant region (IGHM) of various economically important fish species, recognizing both secreted IgM (serum/mucus) and membrane-bound IgM (B cell surface). All antibodies are purified by Protein A/G affinity, with purity >95%, and have been validated in multiple platforms including ELISA, FCM, IF, and WB, suitable for vaccine efficacy evaluation, B‑cell subset analysis, tissue expression detection, and immune monitoring.

Recent reports of Hand, Foot, and Mouth Disease (HFMD) in Japan have drawn increasing public health attention. According to the Japan Institute for Health Security (JIHS), the cumulative number of HFMD cases nationwide has exceeded 11,600 in 2026. During the week of May 25--31 alone, six prefectures, including Fukuoka, Miyazaki, and Kagoshima, reported case numbers above the official alert threshold, prompting local health authorities to issue outbreak warnings earlier than in previous years.

In May 2026, AntibodySystem products continued to support cutting-edge research across multiple scientific disciplines. Studies citing our reagents were published in journals including Science China Life Sciences, Journal of Translational Medicine, Cell Reports, European Journal of Medicinal Chemistry, and Journal of Medical Virology.

On May 18, the government of the Democratic Republic of the Congo (DRC) reported that the newly emerged Ebola outbreak in Ituri Province continues to spread. Authorities have recorded 116 suspected deaths, while another 435 suspected cases remain under observation and treatment. Meanwhile, neighboring Uganda has also reported a fatal imported case. The World Health Organization (WHO) has declared the outbreaks in the DRC and Uganda a "Public Health Emergency of International Concern (PHEIC)." Rwanda, Tanzania, Zambia, and other neighboring countries have subsequently strengthened border screening and public health surveillance measures. At a time when the global public health system is still recovering from the aftermath of COVID-19, the resurgence of Ebola virus — one of the world's most lethal pathogens — has once again drawn international attention.

In April 2026, AntibodySystem products continued to support cutting-edge multidisciplinary research, contributing to studies published in journals including Nature Publishing Group journals, Angewandte chemie International Edition, EMBO Molecular Medicine, Bioorganic Chemistry, Cancers, and Sensors. These studies span key areas such as early cancer diagnostics, bone metabolism disorders, renal fibrosis, neuroimaging, viral vaccines, and tumor immunotherapy, further advancing innovation in frontier technologies and translational medicine.

The recent outbreak aboard the Caribbean Princess serves as another reminder that norovirus remains one of the most challenging viral pathogens in public health settings, particularly in crowded and enclosed environments. Its exceptionally low infectious dose, environmental persistence, and rapid transmission dynamics continue to complicate outbreak control efforts worldwide. At the same time, the absence of robust culture systems and approved vaccines has posed significant scientific and technical barriers to therapeutic and vaccine development. Nevertheless, continued advances in organoid-based infection models, VLP technologies, recombinant protein platforms, and structural virology are rapidly accelerating progress in the field. Future studies focused on VP1, RdRp, and virus-host interaction mechanisms are expected to remain central to the development of next-generation norovirus vaccines and diagnostics.

According to data released by the government of Bangladesh on April 29, a severe measles outbreak has been ongoing since mid-March, resulting in 227 child fatalities and approximately 35,000 suspected infections. The majority of cases have occurred in children aged 6 months to 5 years. This outbreak is considered one of the most severe measles epidemics in the country in recent decades. Data cited from the World Health Organization indicate that between March 15 and April 14 alone, more than 19,000 suspected cases were reported, with nearly 3,000 laboratory-confirmed infections. Declining vaccination coverage in recent years has been identified as a major contributing factor to the rapid spread of the outbreak, particularly in remote and underserved regions where access to healthcare remains limited.

A suspected cluster of hantavirus infections has recently been reported aboard the polar expedition cruise vessel Hondius, sailing in the Atlantic Ocean. To date, seven cases have been identified, including three fatalities. Hantaviruses are typically transmitted via rodents, and clustered occurrences in confined environments such as cruise ships are considered highly unusual. This incident has drawn increased attention from the global public health community.